Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis

NCT00411723 is registered in ClinicalTrials.gov with Artielle ImmunoTherapeutics as lead sponsor.

NCT NCT00411723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00411723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Lead sponsor
Artielle ImmunoTherapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
December 31, 2006
Completion date
May 31, 2009
Enrollment
34 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, chronic progressive, multiple sclerosis, relapsing-remitting